New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease

Leo Bon,Angelika Banaś,Inês Dias,Inês Melo-Marques,Sandra M. Cardoso,Sílvia Chaves,M. Amélia Santos

DOI: https://doi.org/10.3390/pharmaceutics16020281

IF: 6.525

2024-02-16

Pharmaceutics

Abstract:Alzheimer's disease (AD) is the most common form of dementia with no cure so far, probably due to the complexity of this multifactorial disease with diverse processes associated with its origin and progress. Several neuropathological hallmarks have been identified that encourage the search for new multitarget drugs. Therefore, following a multitarget approach, nine rivastigmine–indole (RIV-IND) hybrids (5a1-3, 5b1-3, 5c1-3) were designed, synthesized and evaluated for their multiple biological properties and free radical scavenging activity, as potential multitarget anti-AD drugs. The molecular docking studies of these hybrids on the active center of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) suggest their capacity to act as dual enzyme inhibitors with probable greater disease-modifying impact relative to AChE-selective FDA-approved drugs. Compounds 5a3 (IC50 = 10.9 μM) and 5c3 (IC50 = 26.8 μM) revealed higher AChE inhibition than the parent RIV drug. Radical scavenging assays demonstrated that all the hybrids containing a hydroxyl substituent in the IND moiety (5a2-3, 5b2-3, 5c2-3) have good antioxidant activity (EC50 7.8–20.7 μM). The most effective inhibitors of Aβ42 self-aggregation are 5a3, 5b3 and 5c3 (47.8–55.5%), and compounds 5b2 and 5c2 can prevent the toxicity induced by Aβ1-42 to cells. The in silico evaluation of the drug-likeness of the hybrids also showed that all the compounds seem to have potential oral availability. Overall, within this class of RIV-IND hybrids, 5a3 and 5c3 appear as lead compounds for anti-AD drug candidates, deserving further investigation.

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the treatment of Alzheimer's disease (AD). Currently, AD is a complex multifactorial disease, and there is no cure yet. The existing treatment methods can only relieve symptoms but cannot stop or slow down the progress of the disease. The paper mentions that due to the complexity of AD, single - target drugs have limited effects. Therefore, researchers have turned to the design and development of multi - target drugs, hoping to act on multiple pathological processes of AD simultaneously, such as the inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), the inhibition of β - amyloid (Aβ) aggregation, antioxidant activity and neuroprotective effects, etc. Specifically, this paper designed and synthesized nine new rivastigmine - indole (RIV - IND) hybrids and evaluated their multiple biological activities as potential multi - target anti - AD drugs. These compounds aim to achieve simultaneous intervention on multiple AD - related targets by combining two active ingredients, rivastigmine and indole, and thus may have better disease - modifying effects.

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer's Disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases

Discovery of Novel Rivastigmine-Hydroxycinnamic Acid Hybrids As Multi-Targeted Agents for Alzheimer's Disease.

Design, Synthesis and Evaluation of Rivastigmine and Curcumin Hybrids As Site-Activated Multitarget-Directed Ligands for Alzheimer's Disease Therapy.

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease

Donepezil‐indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Design, Synthesis, and Biological Evaluation of Novel Tetrahydroacridin Hybrids with Sulfur-Inserted Linkers as Potential Multitarget Agents for Alzheimer's Disease

Quinazolinone-Hydrazine Cyanoacetamide Hybrids as Potent Multitarget-Directed Druggable Therapeutics against Alzheimer's Disease: Design, Synthesis, and Biochemical, In Silico, and Mechanistic Analyses

Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as Multifunctional Agents for the therapy of Alzheimer's Disease.

Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases

Design, Synthesis and Preliminary Biological Evaluation of Rivastigmine-INDY Hybrids as Multitarget Ligands Against Alzheimer's Disease by Targeting Butyrylcholinesterase and DYRK1A/CLK1 Kinases

Apigenin-rivastigmine Hybrids As Multi-Target-directed Liagnds for the Treatment of Alzheimer's Disease.

Design, Synthesis, and Biological Evaluation of Piperazine and N-Benzylpiperidine Hybrids of 5-Phenyl-1,3,4-oxadiazol-2-thiol as Potential Multitargeted Ligands for Alzheimer's Disease Therapy

An In Vitro and In Vivo Investigation

Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy

Novel styryl-thiazole hybrids as potential anti-Alzheimer's agents

Multi-Target-Directed Cinnamic Acid Hybrids Targeting Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease